Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 10493277

Rofecoxib.

L J Scott·H M Lamb
View original source ↗Export metadata ↓

Abstract

Rofecoxib selectively inhibits cyclo-oxygenase-2 in a dose-dependent manner in humans. No significant inhibition of cyclo-oxygenase-1 is observed with rofecoxib up to doses of 1000 mg. In 4 large double-blind randomised trials performed in patients with osteoarthritis, rofecoxib 12.5 and 25 mg/day significantly improved physical functioning, assessed using the Western Ontario and McMasters Universities Osteoarthritis Index and patient or investigator global assessment, compared with placebo. In addition, rofecoxib showed similar clinical efficacy to that observed with diclofenac 50 mg 3 times daily, ibuprofen 800 mg 3 times daily and nabumetone 1500 mg once daily. Rofecoxib is also an effective analgesic in patients with primary dysmenorrhoea or postoperative dental pain and demonstrates similar analgesic efficacy to that of naproxen sodium and ibuprofen. Rofecoxib is generally well tolerated. The most common adverse events associated with rofecoxib are diarrhoea, headache, nausea and upper respiratory tract infection. There was a significantly lower incidence of upper-gastrointestinal adverse events (perforations, ulcers and bleeds) in patients with osteoarthritis receiving rofecoxib 12.5, 25 or 50 mg/day than in those receiving ibuprofen, diclofenac or nabumetone.

Explore related subjects

AnalgesicsClinical Trials as TopicCyclooxygenase InhibitorsDrug InteractionsDysmenorrheaEnzyme InhibitorsHumansLactonesOsteoarthritisSulfonesComparative StudyJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L J Scott, H M Lamb. 1999. Rofecoxib.. https://doi.org/10.2165/00003495-199958030-00016

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

[Chronic pain patient's acceptance and satisfaction with their analgesic medication. Development and validation of the QAMPAS questionnaire].

BACKGROUND: A newly developed questionnaire to measure the satisfaction of chronic pain patients with their analgetic treatment is introduced. METHODS: Based on pilot studies, a multidimensional questionnaire (QAMPAS) for the measurement of patient satisfaction was developed. In addition to a module on general patient satisfaction, it includes two specific modules with regard to medical treatment using tablets and transdermal systems (patches). In a validation study the questionnaire was administered at two measurement points to ambulatory chronic pain patients. RESULTS: The QAMPAS subscales possess satisfactory psychometric properties. Medication-specific satisfaction shows a well-differentiated multidimensional structure. With minor limitations, correlations with the general patient satisfaction module and the SF-36 and BPI subscales indicate it to be a valid instrument. CONCLUSION: The QAMPAS questionnaire is a standardized instrument with satisfactory psychometric properties for the measurement of patient satisfaction with their analgesic treatment.

Analgesics↗
PubMed2006

[Preoperative pain training. No influence on postoperative pain perception in patients undergoing cardiac surgery].

BACKGROUND: The present research was performed to investigate the influence of preoperative information on pain given by the nursing staff on postoperative pain perception in patients. METHODS: A randomized controlled interventional study was conducted in 93 patients undergoing cardiac surgery at the University Hospital Erlangen. One day before the surgery all participants were evaluated using the Eysenck Personality Questionnaire, patients of the treatment group were additionally trained by a member of the nursing staff in pain behaviour. After discharge from the intensive care unit the pain experience of the patients was evaluated using standardized questionnaires. RESULTS: Of the 93 patients, 73 finished the study protocol and were analyzed. The pain experience was not significantly different between the two study groups. Patients with increased levels of neuroticism (characterized by emotional lability) regardless of study group more frequently reported pain values above 3/10. CONCLUSION: No significant modulation of postoperative pain experience was achieved by preoperative information on pain. However, it cannot be ruled out that this intervention, particularly in view of the reduction in anxiety, may form a significant element of perioperative pain management.

Analgesics↗
PubMed2005

Nicotinic receptor involvement in antinociception induced by exposure to cigarette smoke.

Direct exposure of rats to tobacco smoke induces antinociception. We presently investigated if this antinociception is mediated via nicotinic and/or mu-opioid receptors. Adult male rats were surgically implanted with Alzet osmotic minipumps that delivered either saline (control), the nicotinic antagonist mecamylamine, or the opiate antagonist naltrexone (3 mg/kg/day i.v. for 21 days). Nocifensive responses were assessed on alternate days using tail-flick reflex latency (TFL) over a 3-week period. During the second week, the rats were exposed to concentrated cigarette smoke in an environmental chamber for 6 h/day for 5 consecutive days; a control group was similarly exposed to filtered cigarette smoke. Rats receiving mecamylamine and naltrexone exhibited a significant weight loss after the first day of infusion. All treatment groups additionally exhibited significant weight loss during exposure to unfiltered or filtered smoke. The saline group exhibited significant antinociception on the first day of smoke exposure with rapid development of tolerance. The mecamylamine and naltrexone groups did not exhibit significant antinociception. Controls exposed to filtered smoke (with approximately 50% lower nicotine concentration) also exhibited significant analgesia on the first exposure day with rapid development of tolerance. Exposure to high levels of cigarette smoke, or to filtered smoke with a lower nicotine concentration in the vapor phase, induces antinociception with rapid development of tolerance. The antinociceptive effect appears to be mediated via nicotinic and mu-opioid receptors.

Analgesics↗